|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Polycystic_ovary_syndrome
gptkb:Glucophage_XR
gptkb:Riomet
gptkb:Dovato
gptkb:Dapagliflozin/_Glimepiride
gptkb:dapagliflozin
gptkb:insulin_lispro
gptkb:Fortamet
gptkb:Glucophage
|
|
gptkbp:activities
|
increases insulin sensitivity
decreases hepatic glucose production
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
|
|
gptkbp:category
|
B
|
|
gptkbp:clinical_trial
|
studied for cancer treatment
studied for weight management
studied for aging
|
|
gptkbp:contraindication
|
renal impairment
acute or chronic metabolic acidosis
|
|
gptkbp:developed_by
|
French lilac
|
|
gptkbp:discovered_by
|
gptkb:1922
|
|
gptkbp:dosage_form
|
500 mg to 2000 mg daily
|
|
gptkbp:formulation
|
extended-release
immediate-release
|
|
gptkbp:has_ability
|
weight loss
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
metformin
|
|
gptkbp:ingredients
|
C4 H11 N5
|
|
gptkbp:interacts_with
|
gptkb:beer
iodinated contrast media
|
|
gptkbp:is_atype_of
|
A10 B A02
|
|
gptkbp:is_available_on
|
gptkb:tablet
gptkb:item
|
|
gptkbp:is_used_for
|
type 2 diabetes
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:Merck
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:notable_work
|
RECORD trial
CANTOS trial
LEADER trial
ACCORD trial
ADVANCE trial
CANVAS trial
DPP study
EMPA-REGOUTCOME trial
ORIGIN trial
UKPDS study
|
|
gptkbp:side_effect
|
nausea
diarrhea
lactic acidosis
gastrointestinal upset
lowers LDL cholesterol
|
|
gptkbp:sugar_content
|
lowers blood sugar levels
|
|
gptkbp:suitable_for
|
gptkb:healthcare_organization
gptkb:World_Health_Organization
severe heart failure
severe liver disease
type 1 diabetes
|
|
gptkbp:treatment
|
polycystic ovary syndrome
|
|
gptkbp:uses
|
reduces risk of cardiovascular events
|